创新药企ETF(560900)盘中涨超1%，连续3日获资金净流入，政策红利不断加码，创新药赛道迎来发展新机遇

Group 1 - The core viewpoint of the news highlights the positive market response and policy support for the innovative drug sector, particularly through the recent ETF performance and government procurement policies [1][2]. - The innovative drug ETF (560900) experienced a significant increase in trading volume and net inflow of funds, reaching a new high in both scale and shares [1]. - The National Medical Insurance Administration has initiated the 11th batch of centralized drug procurement, establishing clear guidelines that protect innovative drugs, thereby boosting confidence in R&D and commercialization for innovative drug companies [2]. Group 2 - The new procurement policy is expected to enhance the commercialization path for innovative drugs, facilitating market penetration and sales growth [2]. - The innovative drug ETF closely tracks the CSI Innovative Drug Industry Index, which includes a maximum of 50 representative listed companies involved in innovative drug R&D [2]. - Morgan Asset Management is integrating its global technology investment products to help investors capitalize on opportunities in quality tech companies amid the rise of AI-driven technological advancements [2].